Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cytogenetic polyclonality in hematologic malignancies.

B Johansson1, R Billström, K Broberg

  • 1Department of Clinical Genetics, Lund University Hospital, Sweden. bertil.johansson@klingen.lu.se

Genes, Chromosomes & Cancer
|August 19, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytogenetic evolution patterns in non-Hodgkin's lymphoma.

Blood·1995
Same author

Immune parameters in a longitudinal study of a very old population of Swedish people: a comparison between survivors and nonsurvivors.

The journals of gerontology. Series A, Biological sciences and medical sciences·1995
Same author

[Lessons learned from the Råneälv accident. Role distribution important during crisis intervention].

Lakartidningen·1995
Same author

Continuity and discontinuity in the anti-V3 IgG response of human immunodeficiency virus type 1-infected persons in a cross-sectional and longitudinal study using synthetic peptides.

The Journal of infectious diseases·1995
Same author

Adenosine A2A receptors stimulate acetylcholine release from nerve terminals of the rat hippocampus.

Neuroscience letters·1995
Same author

[Private health insurance can improve health care].

Lakartidningen·1995

Cytogenetic polyclonality occurs in 2.6% of acute myeloid leukemias (AML) and varies across hematologic malignancies. Previous genotoxic exposure significantly increases polyclonality in therapy-related AML and myelodysplastic syndromes (MDS).

Area of Science:

  • Hematology
  • Cytogenetics
  • Oncology

Background:

  • Cytogenetic polyclonality, the presence of multiple unrelated clones, is a recognized phenomenon in hematologic malignancies.
  • Understanding the frequency and influencing factors of polyclonality is crucial for diagnosis and prognosis.

Purpose of the Study:

  • To determine the frequency of cytogenetic polyclonality in various hematologic malignancies.
  • To investigate the influence of morphologic subgroup, age, gender, and prior genotoxic exposure on polyclonality incidence.

Main Methods:

  • Cytogenetic analysis of 2,243 hematologic malignancies.
  • Survey of 17,733 published karyotypically aberrant cases.
  • Analysis of incidence based on malignancy type, FAB classification, B-/T-cell lineage, age, gender, and treatment history.

Related Experiment Videos

Main Results:

  • Cytogenetic polyclonality was identified in 2.6% of AML, 1.6% of MDS, 0.8% of ALL, 13% of AUL, 9.1% of Ph- CML, 1.5% of CMD, and 2.8% of CLD.
  • Incidence varied significantly among AML FAB types, CLD entities, and B-/T-cell CLD.
  • Therapy-related AML and MDS showed significantly higher polyclonality rates than de novo cases.

Conclusions:

  • Cytogenetic polyclonality is present in a subset of hematologic malignancies, with varying frequencies across subtypes.
  • Previous genotoxic exposure is a significant risk factor for developing cytogenetic polyclonality in AML and MDS.
  • Polyclonality incidence is not significantly influenced by age, gender, or broad lineage (B-/T-cell ALL), but shows specific variations within AML and CLD entities.